Dange S V, Patki P S, Bapat V M, Shrotri D S
Department of Pharmacology, B. J. Medical College, Pune.
Indian J Physiol Pharmacol. 1987 Jan-Mar;31(1):25-9.
'Arogyavardhini'-an indigenous formulation was evaluated for its hepatoprotective activity in rats, using two models of carbon tetrachloride (CCl4) hepatic damage, one simulating vital hepatitis and the other simulating fatty change. The protective effect was assessed from serum aspartate transaminase (AST) and alkaline phosphatase levels and from histopathological changes in liver. The results revealed that 'Arogyavardhini' (5 mg/100g, PO daily) was effective in minimizing the changes in serum levels of AST and alkaline phosphatase induced by CCI. The protective effect was also evident on histopathological examination.
对一种本土制剂“Arogyavardhini”进行了评估，在大鼠中使用两种四氯化碳（CCl4）肝损伤模型来研究其肝脏保护活性，一种模拟暴发性肝炎，另一种模拟脂肪变性。通过血清天冬氨酸转氨酶（AST）和碱性磷酸酶水平以及肝脏的组织病理学变化来评估保护作用。结果显示，“Arogyavardhini”（5毫克/100克，每日口服）能有效减轻由CCl4诱导的血清AST和碱性磷酸酶水平的变化。组织病理学检查也显示出明显的保护作用。
